Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2004

View Archived Issues

airPharma and Britannia sign licensing agreement for asthma drug AP-0016

Ziopharm licenses proprietary form of isophosphoramide mustard

Somaxon exercises option to nalmefene for impulse control disorders

Amgen establishes Amgen Ventures

Genelabs receives milestone from GSK for hepatitis E vaccine

Bridge financing to fund initiation of Oxycyte phase II trial

Tracleer progresses towards approval in Japan

Serono and Nautilus to develop next generation of human growth hormone

Xoma licenses BPI to Zephyr Sciences

Canadian approval for new trial of XP-828L for psoriasis

PDE5 inhibitors for the treatment of diabetes

Researchers at Wyeth describe compounds for the treatment of anxiety and depression

Contrast agents described in patent literature

Roche patents non-nucleoside reverse transcriptase inhibitors

Two series of oxazolidinone antibacterials claimed by AstraZeneca

Medicure discloses cardioprotective agents

Evidence for the protective effects of HBV-ISS vaccine against HBV infection

Novel plasmid DNA vaccines under development for CMV infection

Amantadine reduces fatigue associated with interferon/ribavirin in hepatitis C patients

Lower incidence of death and MI found with pexelizumab after CABG surgery

Therapeutic benefits of valsartan plus simvastatin in patients with hypertension and hyperlipidemia

Antidepressant and anxiolytic effects of neuronal nicotinic acetylcholine receptor ligands

Antitumor effects reported for EKB-569 plus FOLFIRI in advanced colorectal cancer

Neuroprotection by novel selective NMDA receptor antagonist

Preliminary data on the antitumor efficacy and safety of patupilone in NSCLC

Inhibitors of bacterial cell wall synthesis from Johnson & Johnson

Complete protection against S. aureus by dual antibody approach

Inflammatory pain targeted by selective estrogen receptor beta agonist

CYC-202 as potential new treatment for lupus nephritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...